Scientists test powerful drug cocktail against Tough-to-Treat lung cancer
NCT ID NCT04224337
Summary
This study tested a combination of three drugs—durvalumab, doxorubicin, and ifosfamide—in patients with a rare and aggressive form of non-small cell lung cancer called pulmonary sarcomatoid carcinoma. The main goal was to see how well this combination could shrink tumors and control the disease, while also closely monitoring side effects. The trial involved 16 adult patients with advanced or recurrent cancer who met specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Seoul National University Hospital
Seoul, Seoul, South Korea
Conditions
Explore the condition pages connected to this study.